6FCZ
| Model of gC1q-Fc complex based on 7A EM map | 分子名称: | Complement C1q subcomponent subunit A, Complement C1q subcomponent subunit B, Complement C1q subcomponent subunit C, ... | 著者 | Ugurlar, D, Howes, S.C, de Kreuk, B.J.K, de Jong, R.N, Beurskens, F.J, Koster, A.J, Parren, P.W.H.I, Sharp, T.H, Gros, P, Koning, R.I. | 登録日 | 2017-12-21 | 公開日 | 2018-02-28 | 最終更新日 | 2018-10-24 | 実験手法 | ELECTRON MICROSCOPY (10 Å) | 主引用文献 | Structures of C1-IgG1 provide insights into how danger pattern recognition activates complement. Science, 359, 2018
|
|
1N0X
| Crystal Structure of a Broadly Neutralizing Anti-HIV-1 Antibody in Complex with a Peptide Mimotope | 分子名称: | 3-CYCLOHEXYL-1-PROPYLSULFONIC ACID, B2.1 peptide, GLYCEROL, ... | 著者 | Saphire, E.O, Montero, M, Menendez, A, Irving, M.B, Zwick, M.B, Parren, P.W.H.I, Burton, D.R, Scott, J.K, Wilson, I.A. | 登録日 | 2002-10-15 | 公開日 | 2004-04-13 | 最終更新日 | 2017-06-21 | 実験手法 | X-RAY DIFFRACTION (1.8 Å) | 主引用文献 | Crystal Structure of a Broadly Neutralizing Anti-HIV-1 Antibody in Complex with a Peptide Mimotope To be Published
|
|
6WVZ
| Crystal structure of anti-MET Fab arm of amivantamab in complex with human MET | 分子名称: | 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose, ... | 著者 | Cardoso, R.M.F. | 登録日 | 2020-05-07 | 公開日 | 2021-04-28 | 最終更新日 | 2023-10-18 | 実験手法 | X-RAY DIFFRACTION (3.1 Å) | 主引用文献 | Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET. J.Biol.Chem., 296, 2021
|
|
5VAA
| |
6T3J
| Dual Epitope Targeting by Anti-DR5 Antibodies | 分子名称: | IgG1-hDR5-01-Heavy Chain, IgG1-hDR5-01-Light Chain, IgG1-hDR5-05-Heavy Chain, ... | 著者 | Tauchert, M.J, Augustin, M, Krapp, S, Overdijk, M.B, Breij, E.C.W, Hibbert, R.G. | 登録日 | 2019-10-11 | 公開日 | 2020-09-16 | 最終更新日 | 2024-10-16 | 実験手法 | X-RAY DIFFRACTION (3.05 Å) | 主引用文献 | Dual Epitope Targeting and Enhanced Hexamerization by DR5 Antibodies as a Novel Approach to Induce Potent Antitumor Activity Through DR5 Agonism. Mol.Cancer Ther., 19, 2020
|
|